Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2006

MethylGene and Envivo Receive $1.5M to Advance Huntington’s Disease Research

  • MethylGene and EnVivo Pharmaceuticals entered into a collaborative agreement with CHDI, a nonprofit organization that is pursuing biotechnology approaches to rapidly discover and develop treatments for Huntington’s disease (HD). MethylGene and EnVivo formed a collaboration in February, 2005 focused on MethylGene’s HDAC technology for use in neurodegenerative diseases.

    In this collaboration, CHDI will provide financial and preclinical research support to MethylGene to enhance its collaboration with EnVivo Pharmaceuticals to progress histone deacetylase (HDAC) inhibitors for the treatment of HD. MethylGene will receive up to $1.5 million in initial funding for the identification, design, and synthesis of new isotype-selective HDAC inhibitors for potential use in treating Huntington’s disease as well as support for other preclinical pharmacology testing. MethylGene and EnVivo retain the exclusive right to develop and commercialize any clinical candidates that arise from the collaboration.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »